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Abstract: Dextran-coated superparamagnetic nanopar-
ticles (MNPs) have widespread biomedical applications.
The superparamagnetic behavior, specifically regulated
size, and smooth morphology are crucial requirements for
essentially all of these applications. Presented herein is an
innovative double-coating strategy that would allow for a
size-controlled synthesis of MNPs. Small monocrystalline
iron oxide nanoparticles (MIONs) were first synthesized,
which served as the source of superparamagnetic proper-
ties. These MIONs were then treated in an acetate buffer
containing biocompatible dextran polymer. Under such an
environment, the colloidal MIONs would be quickly
agglomerated by the acetate ions, and the formed coales-
cent body of MION would then be stabilized simultane-
ously by coating with dextran. By regulating the MION or
dextran concentration as well as the thermal incubation
time, the sizes of these first formed nanoparticles (termed
1st-NPs) could be readily controlled. A second dextran
coating step was further applied to smoothen the 1st-NPs
in attaining a final product (termed 2nd-NPs). The 2nd-
NPs exhibited robust storage stability because of the addi-
tional coating shell. Results successfully confirmed the
plausibility of this approach, as these MNPs displayed not
only a smooth outline and a narrow size distribution but
also the essential superparamagnetic behavior and a signif-
icantly prolonged stability on storage.  2009 Wiley Peri-
odicals, Inc. J Biomed Mater Res 92A: 1468–1475, 2010
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INTRODUCTION
Iron oxide-based magnetic nanoparticles (MNPs)
have attracted great interest owing to their wide-
spread applications in biomedicine including sens-
ing,1 cell labeling,2 imaging,3 targeted delivery of
drugs4 and genes,5 as well as localized therapeutic
hyperthermia.6 Several comprehensive reviews con-
cerning the properties, syntheses, and applications
can be found in the literature.7–9 Generally speaking,
these MNPs comprise a magnetic core consisting of
magnetite (Fe3O4) or maghemite (Fe2O3), which is sur-
rounded by a coating of a biocompatible polymer
such as dextran or starch. Although the monocrystal-
line iron oxide nanoparticles (MIONs) serve as the
superparamagnetic resource, the polymer coating pre-
vents MNPs from aggregation because of the intrinsic
magnetic attraction. In addition, the activatable func-
tional groups (e.g. NH2, OH) on the polymer also
allow for conjugation of bioactive compounds such as
drugs or antibodies on the MNP surface for subse-
quent targeting and delivery purposes.
The diameter of the MION core and the overall
hydrodynamic size of MNPs (i.e. MION plus the
polymer shell) are both of critical significance with
regard to in vivo applications. Although nanoparticles
greater than 300 nm in size are known to be seques-
tered in liver and spleen and removed by the mono-
nuclear phagocyte system, particles less than 10 nm in
diameter become small enough for rapid clearance
through extravasations and renal filtration.10,11
Indeed, MNPs with size ranging between 100 and 200
nm in diameter have been reported to possess a long-
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circulating plasma half-life for imaging and target-
ing12 via the so-called enhanced permeability and
retention (EPR) phenomenon of the tumor.13 In con-
trast, it has been demonstrated that magnetic proper-
ties such as magnetic-induced targeting of nanoscale
magnetic particles depend primarily on the magneto-
phoretic mobility; a parameter that is enhanced solely
when increasing the size of the magnetic core.14
Thus far, strategies for MNP synthesis include: (1)
in situ synthesis of MION in the presence of poly-
mer15; (2) in situ synthesis of polymer in the pres-
ence of premade MION16; or (3) direct mixing of
presynthesized MION with polymer together.17
However, some of these strategies involve the use of
a surfactant as emulsifying agent, which is often not
biocompatible and also affects the efficiency for sub-
sequent surface modification with bioactive agents.
Most critically, most of these strategies normally
yielded an ill-defined morphology and an irregular
size distribution for the produced MNPs and lacked
the control of size.
Presented herein is an innovative and facile dou-
ble-coating approach that allows for preparing
MNPs with smooth morphology and desirable size
control, and yet comprising of a large core structure
with high-magnetophoretic mobility while retaining
the essential superparamagnetic behavior for bio-
medical applications. As reported, the monocrystal-
line iron oxide nanoparticles (i.e. MIONs; the pri-
mary constituent of the magnetic core) are stable
without forming tightly associated aggregates in
acidic medium.18 Our previous experiments showed
that this stability of MION can also be alternatively
attained by coating MIONs with a biocompatible
polymer such as dextran and that, in contrast, the
colloidal MION suspension tends to agglomerate in
the presence of acetate ions. Therefore, the underly-
ing hypothesis is that if MION is treated in an ace-
tate buffer containing dextran, both the processes of
forming a coalescent body of MION and stabilizing
this large magnetic core by dextran can take place
in situ and simultaneously. By manipulating the
MION or dextran concentrations in the solution,
and/or by altering the pH or thermal incubation
time of the reaction, a tightly size-controlled struc-
ture of MION can be realized. To further smoothen
the morphology, these first-coated nanoparticles
(termed 1st-NPs) are coated for a second time with
a dextran solution (nanoparticles thus prepared are
termed as 2nd-NPs). A schematic illustration of this
approach is demonstrated in Figure 1. Results suc-
cessfully confirmed the plausibility of the approach,
as the double-coated magnetic nanoparticles not
only display a smooth morphology and size but
also exhibit the essential superparamagnetic behav-




Dextran (from Leuconostoc mesenteroides, MW: 9000–
11,000), ferrous chloride tetrahydrate (FeCl24H2O), ferric
chloride hexahydrate (FeCl36H2O), HCl, and sodium hy-
droxide were purchased from Sigma-Aldrich Chemical Co.
Water was distilled and deionized (ddH2O).
Preparation of the superparamagnetic,
monocrystalline iron oxide nanoparticles
MION was synthesized according to a modified proce-
dure of Kim et al.19 Briefly, a solution containing
0.76 mol/L of ferric chloride and 0.4 mol/L of ferrous
chloride (molar ratio of ferric to ferrous was 2:1) was
prepared at pH 1.7 under N2 protection. The iron solution
was then added dropwise into a 1.5M NaOH solution
under vigorous mechanical stirring. The reaction mixture
was gradually heated (18C/min) to 788C and held at this
temperature for 1 h under stirring and N2 protection. After
separation of the supernatant by using a permanent mag-
net, the wet sol was treated with 0.01M HCl and then soni-
cated for 1 h. The acidified colloidal suspension of MION
was filtered through a 0.45 lm and then a 0.22 lm mem-
brane, followed by condensing to a suspension containing
34 mg Fe/mL using a Millipore (USA) ultrafiltration unit.
Preparation of double-coated magnetic
nanoparticles
To synthesize 1st-NPs, dextran was predissolved into a
pH4 acetate buffer solution. To 3 mL of this solution, 1 mL
of the MION suspension prepared above (pH 5 4) was
added all at once under vigorous agitation. The mixture
was then incubated in a 788C water bath. To regulate the
size of the produced nanoparticles, various concentrations
of dextran and MION as well as different incubation time
Figure 1. Schematic illustration of the proposed double-
coating strategy: (A) precipitation of MION by acetate
buffer only; (B) nanoparticles obtained after treatment with
acetate buffer containing dextran (1st-NPs), and after sec-
ond coating with a dextran solution (2nd-NPs); (C) MIONs
coated with dextran solution only. [Color figure can be
viewed in the online issue, which is available at www.
interscience.wiley.com.]
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were attempted. The resulting 1st-NPs were purified twice
by using a permanent magnet separator.
To prepare the final MNP product (i.e. the 2nd-NPs) pos-
sessing a smooth morphology and particle size, 1 mL of the
above-synthesized 1st-NPs (15 mg Fe/mL) was added into
3 mL of a dextran aqueous solution (320 mg/mL) under
agitation. After incubating the solution at 788C for 15 min,
the final product was separated using a magnetic separator.
Characterization
Morphology was examined by transmission electron mi-
croscopy (TEM) using a JEOL 3011 high-resolution electron
microscope (JEOL, Tokyo, Japan) operated at an acceler-
ated voltage of 300 kv. Samples were prepared by placing
diluted particle suspensions on formvar film-coated copper
grids (01813-F, Ted Pella, USA) and then dried at room
temperature. Particle size was measured by a NICOMP
380 ZLS dynamic light scattering (DLS) instrument (PSS,
Santa Barbara, CA) using the 632 nm line of a HeNe laser
as the incident light. The NICOMP software was employed
to analyze the volume-averaged size. Polymer contents of
both the 1st-NPs and 2nd-NPs were determined by a Q50
thermogravimetric analyzer (TGA; TA Instruments, USA)
under N2 atmosphere at a temperature increase rate of
208C/min from 30 to 6008C. Superparamagnetic properties
were assessed at 258C by using a superconducting
quantum interference device (SQUID) (Quantum Design,
San Diego, CA). Iron contents of the magnetic nanopar-
ticles were measured by means of the inductively coupled
plasma-optical emission spectroscopy (ICP-OES) analysis
using the Perkin–Elmer Optima 2000 DV device (Perkin–
Elmer, Boston, MA). Stability was examined by DLS in
terms of the variation in particle size versus time, after
suspending MNPs into 0.1M PBS solution at room temper-
ature. FTIR was performed on lyophilized samples after
they were compressed into 1-mm thick discs with spec-
troscopic grade KBr.
RESULTS
Figure 1(B) illustrated the two-step process of pro-
ducing the MION-based, dextran-coated MNPs. As
seen, bare MIONs were first synthesized as the
building blocks of the magnetic core. The 1st-NPs
were then generated by suspending the colloidal
bare MIONs into an acetate buffer containing dex-
tran, followed by heating the mixture at 788C for a
certain period of time. After obtaining the 1st-NPs,
the ultimate 2nd-NPs were produced by further
coating and heating the 1st-NPs in a freshly pre-
pared suspending medium containing dextran only.
Results summarized in Table I indicated that parti-
cle sizes of the 1st-NPs could be regulated by alter-
ing several parameters during the first coating step,
including dextran and MION concentration as well
as the thermal incubation time. When pairing data
in samples #2 and #4 or samples #3 and #5 together
for comparison (see Table I), it was obvious that
under the same MION concentration (i.e. either 25 or
15 mg Fe/mL) and incubation time (25 min), reduc-
ing dextran concentration resulted in a increase of
the size of the 1st-NPs. A modest reduction in dex-
tran concentration from 380 to 320 mg/mL led to a
relatively significant change in particle size (from
139.5 nm and 79.7 nm in sample #2 and #3 to 187.2
nm and 96.4 nm in sample #4 and #5, respectively).
Conversely, when dextran concentration and incuba-
tion time were held constant with MION concentra-
tion being reduced by a scale of 10 mg Fe/mL,
such as those seen in samples #1 through #3 and #4
to #5, a dramatic decrease in particle size was
observed. Alternatively, by holding both dextran
and MION concentration in the reaction mixture
unchanged but elevating the incubation time (sam-
ples 3# and #6 through #8) also appeared to enhance
particle growth of the 1st-NPs. Because the main
purpose of the second dextran coating was to
smoothen the surface morphology and stabilize the
MNPs from aggregation by magnetic attraction,
there was no major difference in particle size
between the 1st-NPs and 2nd-NPs.
TEM images of the synthesized MNPs were pre-
sented in Figure 2. The bare MION product dis-
TABLE I
Summary of Experimental Conditions and Size Distributions Following Syntheses
of the 1st-NP and 2nd-NP Products










1 380 34 25 188.1 6 11.8 195.6 6 15.8
2 380 25 25 139.5 6 8.7 152.7 6 13.0
3 380 15 25 79.7 6 6.2 94.0 6 9.1
4 320 25 25 187.2 6 13.1 190.1 6 11.4
5 320 15 25 96.4 6 8.9 107.7 6 8.7
6 380 15 35 112.1 6 7.8 116.1 6 8.0
7 380 15 45 125.5 6 8.8 142.2 6 11.3
8 380 15 55 152.9 6 9.2 158.7 6 12.8
Both the concentrations of dextran and MION were before mixing; the ratio of dextran over MION was fixed at 3/1 in
volume.
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played a homogeneous dispersion with a size distri-
bution of 9 6 1.9 nm, as calculated from the TEM
image [Fig. 2(A)]. As anticipated, acetate ions
induced coagulation of the mono-dispersed, colloidal
iron oxide particles, as clusters of MION sols were
observed for the 1st-NPs [Fig. 2(B)]. Besides its stabi-
lization effect in preventing particles from precipita-
tion, the adhesive dextran polymer appeared to also
act as a cross-linking agent to connect the small
MIONs to form the large clusters of magnetic core
structures. Apparently, dextran was not present in
sufficient amount during the first coating process to
fix the morphological appearance of these particles,
as both the shape and outline of these 1st-NPs were
rather irregular. Indeed, dextran coating could only
be observed vaguely, when the TEM image of the
particle was carried out at a much higher magnifica-
tion [see insert in Fig. 2(B)]. Nonetheless, following
an additional dextran coating on the 1st-NPs, the
2nd-NPs exhibited smooth outline with tightly con-
trolled size [Fig. 2(C)]. Unlike the first step of MNP
preparation, the second coating event occurred pri-
marily on the particle surface, as dextran polymer
could be easily identified by TEM under a high mag-
nification [see insert in Fig. 2(C)]. Besides, there are
some satellite-like small particles within the 2nd-
MNP. These small particles, however, were sup-
posed to be largely removed during the washing
process. The remaining amount of small particles,
whether by volume or by weight, was low compared
with the whole MNP. There was slight probability of
retaining some of the uncoated MIONs, although it
is difficult to identify the coating shell in the TEM
image, simply because the positively charged
MIONs were exposed to a high concentration of the
negative-charged dextran solution. In other words,
the outmost layer of the 2nd-NP was virtually all of
dextran, without the presence of naked MION. The
observed good stability of the 2nd-NP, shown later,
was actually attributed to the thick and complete
dextran coating shell.
Measurements using a thermogravimetric analyzer
(TGA) of the polymer contents of these synthesized
MNPs also gave consistent results. As shown by the
data in Figure 3, the 1st-NPs yielded a 10.01%
weight loss using bare MIONs as the standard (i.e.
100% weight remaining). Obviously, this weight loss
was primarily attributed to the introduction of dex-
tran to bare MIONs during synthesis of the 1st-NPs.
As expected, the 2nd-NPs displayed a total weight
loss of 17.30%, 7.29% more than that of the 1st-NPs,
because of the incorporation of additional dextran
polymer to the previously coated nanoparticles.
Figure 4 demonstrated the stability of the synthe-
sized MNPs. Although there was an abrupt elevation
of size in the 1st-NP suspension after 2 h of incuba-
tion in PBS solution (pH 7.4) at room temperature,
the 2nd-NP suspension remained virtually stable
during the entire course of storage of 120 h under
the same experimental conditions.
The magnetic properties of MIONs and 2nd-NPs
were also examined by SQUID, and the results were
shown in Figure 5. Both MION and the 2nd-NP
exhibited a typical superparamagnetic behavior in
which particles did not remain magnetized in the ab-
sence of an external magnetic field, as reflected by
Figure 2. Transmission electron microscopy (TEM) images of (A) MIONs; (B) 1st-NPs; and (C) 2nd-NPs (i.e. final). Both
the images of B and C corresponded to 2# in Table I.
Figure 3. Thermogravimetric analysis (TGA) curves of
MIONs (top), 1st-NPs (middle), and 2nd-NPs (bottom)
obtained at a temperature increase rate of 208C/min from
30 to 6008C under nitrogen atmosphere. The 1st-NPs and
2nd-NPs corresponded to 2# in Table I. [Color figure can
be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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the overlap between the magnetization and demag-
netization curves and absence of a hysteresis loop.
In addition, the 2nd-NP preparation displayed a sat-
uration magnetic moment of 89.1 emu/g(Fe) that
was in close resemblance with that (93.2 emu/g(Fe))
of the native MION without dextran coating.
DISCUSSION
Existing dextran-coated superparamagnetic nano-
particles were generally synthesized by coprecipita-
tion of ferrous and ferric salts in a dextran solution
in the presence of a strong base such as NaOH or
NH4OH. Although this strategy of forming dextran-
coated nanoparticles was completed in single step, it
nevertheless lacked the capability and flexibility to
regulate the size and morphology of the final prod-
uct. To overcome such shortcomings, a facile and ro-
bust approach that included a sequence of three
individual and independent procedures was devel-
oped. The first step was to synthesize small diameter
monocrystalline iron oxide nanoparticles (MIONs)
possessing the superparamagnetic behavior that was
essential for the majority of biomedical applications.
As being recognized, MION remained stable without
forming aggregates in the HCl solution (pH 4). This
was because MION carried abundant superficial
hydroxyl groups that were protonated (FeOH2þ)
in acidic medium to produce positive surface
charges, thereby preventing them from coagulation.
Increasing pH, MION will lose its positive superfi-
cial charge and eventually aggregate and precipitate.
Coincidently, the isoelectric point (PI) of MION was
experimentally determined to be around 6.4 and
its zeta potential in a pH4 HCl solution was
þ25.4 mV.20–22 The purpose of this independent
synthesis of MION was that it would allow for an
open choice of conditions for subsequent polymer
coating and size control.
The second step, termed first coating because it
involved coating MION with dextran in the exis-
tence of acetate ions, was primarily for size regula-
tion. As reported, the colloidal MION was easily sur-
face-modified by certain carboxylate-containing com-
pounds (RCOO2) including dimercaptosuccinate,
citrate, and tartarate.23,24 However, the MION sus-
pension precipitated when reacting with acetate.
This phenomenon, in major part, was because of the
reaction between superficial hydroxyl groups on
MION (FeOH) and carboxylate ions to form
FeOC(O) R linkages, a similar procedure as in
literature,23,24 which was herein testified by FTIR,
as shown in Figure 6. A new absorbance peak at
1404 cm21, which corresponded to the symmetric
vibration of the CO bond, was identified when
comparing the FTIR spectra with that of MION
alone. The new formatoin of the linkage dramatically
subtracted the stability effect stemming from the su-
perficial hydroxyl groups. In addition, hydration of
acetate ions and hence their ability to separate water
molecules from the lyophilic MION according to the
Hofmeister rule25 was another cause of the precipi-
tating power of acetate ions on MION. In contrast,
Figure 5. Magnitization/demagnitization curves of
MION (top) and 2nd-NP (bottom) by SQUID at 258C. The
2nd-NP was the sample of 2# in Table I. No hysteresis
loop was observed in either curve, indicating the presence
of superparamagnetic behavior for both MION and the
double-coated product (i.e. 2nd-NPs). Both types of nano-
particles also displayed a similar leverage of saturation
magnitization (Ms), as reflected by almost overlapped pla-
teaus. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
Figure 4. Stability of the 1st-NPs (A) and 2nd-NPs (B)
corresponding to 2# in Table I, stored in PBS solution
(0.1M, pH 5 7.4).
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iron-oxide-based magnetic nanoparticles were often
stabilized by coating with a dextran polymer via
hydrogen bonds formed between the hydroxyl
groups on both MION and dextran. Owing to the
small size and high-surface area-to-volume of
MION, this coating is normally strong and inde-
pendent of pH. On the basis of such existing knowl-
edge, we hypothesized that if MION is treated in an
acetate buffer containing dextran, then both of the
processes of MION aggregation and dextran coating
can take place in situ and simultaneously. This con-
comitant occurrence of acetate-induced coagulation
and dextran-induced separation of the coalescent
MION would offer the unique benefit of regulating
the particle size of the produced MNPs, as formation
of the final product relies on the competition of two
reaction kinetics; that is, MION aggregation and dex-
tran coating. For instance, if the aggregation rate is
slow as opposed to the rate of coating, such as under
the situation of the presence of a high concentration
of dextran in the acetate buffer, then only small dex-
tran-coated particles would be produced. A signified
example of this case would be when MIONs were
coated in a dextran solution containing no acetate
ions, whereas in theory and practice, only monocrys-
talline structures of iron oxide particles would be
formed [see Fig. 1(C)]. Conversely, if aggregation
takes place quickly when the coating rate is slow,
such as by increasing the MION or acetate concen-
trations or reducing the dextran concentration in the
coating medium, then formation of large MNPs
would be expected. Similar to the extreme case dis-
played in Figure 1(A), MION would precipitate
quickly as a large mass in acetate buffer containing
no dextran. Furthermore, enhanced heating of the
reaction mixture would augment the kinetic energy
of the nanoparticles, thereby accelerating their colli-
sion rates and facilitating MION aggregation. Results
presented in Table I have successfully confirmed our
hypotheses, and by manipulating experimental pa-
rameters such MION or dextran concentrations in
the reaction mixture as well as the thermal incuba-
tion time periods, MNPs with controllable sizes can
be readily produced.
Although this simultaneous aggregation/coating
tactic was capable of regulating the size of the pro-
duced nanoparticles, TEM image in Figure 2(B) still
indicated that the 1st-NPs were nevertheless irregu-
lar in morphology. Experimentally, the 1st-NPs dem-
onstrated poor stability in PBS buffer. It should be
noted that the 1st-NP preparation in many ways,
such as the irregular configurations, closely
resembled to most of the commercial products (e.g.
fliudMAG-CMX; Chemicell, German), except that the
size distribution of our MNPs was more narrower
than those of existing commercial products; a tribute
to this newly developed coating strategy. To prevail
over these hurdles, a second coating process that
paved an extra layer of dextran on the surface of
1st-NPs was adopted. As shown in Figure 2(C), this
additional dextran rendered the surfaces of the final
MNPs notably smooth. More importantly, surface
dextran provides a shielding effect on the surface
energy of these colloidal nanoparticles, thereby pre-
venting them from aggregation during storage. As
demonstrated from results in Figure 4, the stability
of the 1st-NPs was boosted 50-fold by this second
dextran coating, from a period of 2 h to greater than
100 h. Furthermore, the thick shell of dextran on the
surface allows nanoparticles to be loosely associated
via weak van der Waals forces, therefore remaining
in a fluffy conglomerate state after sedimentation
and suitable for redispersion, without encountering
the so-called ‘‘caking’’ event (i.e. by forming a com-
pact cake of tightly bound aggregates) even after
long-term storage in an aqueous medium (data not
shown).
For in vivo applications of magnetic nanoparticles,
such as magnetic targeting and MRI, superparamag-
netic behavior is of paramount importance. As from
its definition, individual particles with superpara-
magnetic property do not maintain intrinsic magnet-
ization in the absence of an external magnetic field,
and therefore, they will not agglomerate in solution
before administration because of lack of magnetic
attraction between particles. However, MION will
only exhibit superparamagentic behavior below cer-
tain size threshold, namely the size of a single mag-
netic domain. The domain size for MION has been
determined to be below 15 nm.26–29 In contrast, the
efficiency of magnetic-mediated interaction such as
targeting depends primarily on the magnetophoretic
Figure 6. FTIR spectrum of MION (A) and the acetate-
treated MION (B). The acetate-treated MION displayed an
extra peak at 1404 cm21, which attributed to the symmetric
vibration of CO from the FeOC(O)  R linkage
between MION and acetate ions.
SYNTHESIS OF STABLE SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES 1473
Journal of Biomedical Materials Research Part A
mobility; a parameter that can be enhanced only by
increasing the size of the magnetic core. To this
regard, the described technology of coalescing and
coating MION simultaneously offers another signifi-
cant benefit. Although the exceedingly thin layer of
dextran between MION crystals would provide a
shielding effect to maintain the individual crystals
under their original size of a single magnetic domain
(size of bare MION was 9 6 1.9 nm) thereby retain-
ing the superparamagnetic behavior, the coexistence
of acetate ions rendered MIONs to flocculate or, in
other words, to form loosely associated fluffy con-
glomerates with large magnetic cores thereby retain-
ing necessary magnetophoretic mobility for biomedi-
cal applications. Results in Figure 5 confirmed the
former event (i.e. superparamagnetism), whereas
TEM findings in Figure 2(C) revealed the latter phe-
nomenon (i.e. large core of MION).
Overall, the described double-coating strategy in
preparing MNPs offers a number of advantages over
currently existing methods. First, it allows for the
synthesis of MNPs with tailored size and smooth-
ened configuration. As discussed previously, the size
and morphology are of paramount significance with
regard to clinical applications of these MNPs. To
dodge the removal by RES and clearance by the kid-
ney and liver systems thereby yielding a long blood
circulating lifetime, it is essential to control the size
of nanoparticles to be around 100–200 nm. In addi-
tion, these physical attributes also dictate the phar-
macokinetics and biodistribution of MNPs under
in vivo situations. Secondly, MNPs synthesized by
means of this new method not only retain the super-
paramagentic behavior of MION that is essential for
virtually all clinical applications but also maintain a
large core structure of MION that is highly respon-
sive to attraction by the external magnetic field
employed during MRI and tumor targeting. Thirdly,
the markedly prolonged stability on storage greatly
facilitates the suitability of these MNPs for biomedi-
cal applications. Last but not least, the simplicity
and flexibility of this new methodology permit
MION to be coated with virtually all types of bio-
compatible polymers containing different functional
groups, thereby enabling surfaces of these MNPs to
be further modified with various recognition moi-
eties (e.g. antibodies) or bioactive ligands (e.g. the
RGD peptide) for targeting. To this regard, the value
of this new coating strategy is prevalent and wide-
spread.
Dr. Victor C. Yang is currently a Chang Kang Scholar
by the Chinese Ministry of Education at the School of
Chemical Engineering, Tianjin University, Tianjin, China
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